Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study.
Vegezzi E, Cortese A, Bergsland N, Mussinelli R, Paoletti M, Solazzo F, Currò R, Ascagni L, Callegari I, Quartesan I, Lozza A, Deligianni X, Santini F, Marchioni E, Cosentino G, Alfonsi E, Tassorelli C, Bastianello S, Merlini G, Palladini G, Obici L, Pichiecchio A. Vegezzi E, et al. Among authors: lozza a. J Neurol. 2023 Jan;270(1):328-339. doi: 10.1007/s00415-022-11336-z. Epub 2022 Sep 6. J Neurol. 2023. PMID: 36064814 Free PMC article.
Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.
Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L. Cortese A, et al. Among authors: lozza a. J Neurol Neurosurg Psychiatry. 2017 May;88(5):457-458. doi: 10.1136/jnnp-2016-315262. Epub 2017 Feb 10. J Neurol Neurosurg Psychiatry. 2017. PMID: 28188196 Free PMC article. No abstract available.
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti M, Antonini G, Di Paolantonio A, Gentile L, Grandis M, Leonardi L, Lozza A, Manganelli F, Mazzeo A, Mussinelli R, My F, Obici L, Maria Pennisi E, Romozzi M, Russo M, Sabatelli M, Salvalaggio A, Tagliapietra M, Tozza S. Luigetti M, et al. Among authors: lozza a. Eur J Neurol. 2022 Jul;29(7):2148-2155. doi: 10.1111/ene.15325. Epub 2022 Mar 28. Eur J Neurol. 2022. PMID: 35289020 Free PMC article.
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D. Cortese A, et al. Among authors: lozza a. J Neurol. 2016 May;263(5):916-924. doi: 10.1007/s00415-016-8064-9. Epub 2016 Mar 16. J Neurol. 2016. PMID: 26984605
Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers.
Salvalaggio A, Coraci D, Cacciavillani M, Obici L, Mazzeo A, Luigetti M, Pastorelli F, Grandis M, Cavallaro T, Bisogni G, Lozza A, Gemelli C, Gentile L, Ermani M, Fabrizi GM, Plasmati R, Campagnolo M, Castellani F, Gasparotti R, Martinoli C, Padua L, Briani C. Salvalaggio A, et al. Among authors: lozza a. J Neurol. 2021 Jan;268(1):189-198. doi: 10.1007/s00415-020-10127-8. Epub 2020 Aug 4. J Neurol. 2021. PMID: 32749600 Free PMC article.
Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis.
Salvalaggio A, Coraci D, Obici L, Cacciavillani M, Luigetti M, Mazzeo A, Pastorelli F, Grandis M, Cavallaro T, Bisogni G, Lozza A, Gemelli C, Gentile L, Russo M, Ermani M, Fabrizi GM, Plasmati R, De Napoli F, Campagnolo M, Castellani F, Salvi F, Fenu S, Devigili G, Pareyson D, Gasparotti R, Rapezzi C, Martinoli C, Padua L, Briani C. Salvalaggio A, et al. Among authors: lozza a. J Neurol. 2022 Apr;269(4):1905-1912. doi: 10.1007/s00415-021-10754-9. Epub 2021 Aug 19. J Neurol. 2022. PMID: 34410494 Free PMC article.
Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D. Cortese A, et al. Among authors: lozza a. J Neurol. 2016 May;263(5):925-926. doi: 10.1007/s00415-016-8116-1. J Neurol. 2016. PMID: 27098978 No abstract available.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
61 results